AstraZeneca Tests Biosimilar Waters Through Bevacizumab JV
This article was originally published in PharmAsia News
AstraZeneca and Japan's Fujifilm Kyowa Kirin Biologics have signed an agreement to set up a UK-based joint venture to develop globally a biosimilar version of bevacizumab, marking the first tentative step into the biosimilars sector by the research-based pharma giant.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.